Bicycle Therapeutics plc (BCYC)
- GuruFocus.com
Bicycle Therapeutics PLC (BCYC) Q1 2024 Earnings: Narrowing Losses Amidst Robust R&D Progress
Comparison with Analyst Estimates and Strategic Developments
- Business Wire
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
CAMBRIDGE, England & BOSTON, May 02, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported recent business progress and financial results for the first quarter ended March 31, 2024.
- Business Wire
Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
CAMBRIDGE, England & BOSTON, April 24, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of two abstracts for poster presentation at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago.
